This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Browse

Telmisartan

Emerging

Long-half-life ARB (~24 hr, longest of the class) that also weakly agonizes PPARγ — making it the only ARB with a real metabolic angle…

Aliases (7)

Micardis · Pritor · Kinzal · Telma · Telday · 4'-[(1,4'-dimethyl-2'-propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1 · 1'-biphenyl]-2-carboxylic acid

TYPICAL DOSE

40 mg

Daily

ROUTE

Oral (tablet)

Oral

CYCLE

Continuous

As prescribed

STORAGE

Room temp; original container

Room temp

Overview

What is Telmisartan?

Telmisartan is an angiotensin II receptor blocker (ARB) FDA-approved for hypertension. Beyond blood-pressure lowering, it has unique partial PPAR-gamma agonism, giving it metabolic benefits that distinguish it from other ARBs.

Key Benefits

Lowers blood pressure and protects against cardiovascular events, improves insulin sensitivity and lipid profile (PPAR-gamma effect), reduces visceral fat in some studies, and has neuroprotective and anti-inflammatory effects investigated for longevity.

Mechanism of Action

Blocks the AT1 angiotensin II receptor, inhibiting vasoconstriction, aldosterone release, and sympathetic activation. Additionally activates PPAR-gamma (the target of thiazolidinedione diabetes drugs), improving adipocyte differentiation, insulin sensitivity, and reducing inflammation.

Pharmacokinetics

PeakHalf-life

Approximate curve — visual aid only, not data-precise PK

▸Brand options5 known

MicardisPritorKinzalTelmaTelday

StatusRx (US), POM (UK), Rx most jurisdictions; not scheduled

Research Indications

Most Effective

Half-life ~24 hours

the longest of any ARB (vs losartan ~6-9 hr, valsartan ~6 hr, irbesartan ~11-15 hr, olmesartan ~13 hr). Once-daily dosing gives true 24-h…

Effective

Partial PPARγ agonist

this is the differentiator. Telmisartan binds PPARγ with affinity ~25-30% of pioglitazone (a full thiazolidinedione PPARγ agonist used fo…

Investigational

Highly lipophilic

best CNS penetration of any ARB; matters for central RAS effects (autonomic tone, possibly cognition in the elderly).

Investigational

Hepatic clearance, not renal

useful in mild-moderate CKD because dose adjustment isn't required.

Peptide Interactions

eplerenone (or spironolactone):

Synergistic

Combined RAS blockade above + below aldosterone — used in heart failure, sometimes in resistant HTN. Hyperkalemia risk is real with this stack; needs K+ moni…

hydrochlorothiazide (HCTZ) / chlorthalidone:

Synergistic

Standard add-on if BP target not reached on telmisartan alone. Fixed-dose combinations exist (Micardis HCT). Diuretic counters any small Na+ retention and am…

tadalafil:

Synergistic

Mild additive BP drop (both vasodilate). Generally fine in healthy users; watch for orthostasis if both started near-simultaneously. Bodybuilder stacks often…

statins, omega-3, magnesium, taurine, beta-alanine, creatine:

Synergistic

Neutral / supportive cardiometabolic stack pieces.

ACE inhibitors (lisinopril, ramipril, etc.):

Avoid

Combined ACEi + ARB increases adverse events (hyperkalemia, AKI, hypotension) without meaningful added benefit — this was the headline finding of ONTARGET. D…

Aliskiren (direct renin inhibitor):

Avoid

Same problem — redundant RAS hit, additive hyperkalemia and renal risk. Contraindicated in diabetics.

K+-sparing diuretics (spironolactone, eplerenone, amiloride, triamterene)

Avoid

at high doses or without monitoring: hyperkalemia risk. Use at therapeutic doses only with K+ checks.

NSAIDs (chronic high-dose):

Avoid

blunt the antihypertensive effect (prostaglandin pathway) and increase AKI risk in volume-depleted users. Occasional NSAID use is fine.

Lithium:

Avoid

ARBs increase lithium levels; not relevant for most users but worth flagging for anyone on lithium.

High-dose K+ supplements:

Avoid

additive hyperkalemia.

Quality Indicators

✓

Pharmacy-dispensed, intact packaging

Prescription tablets in original sealed packaging from a licensed pharmacy.

Generic vs branded

Generics are usually fine but bioavailability can vary slightly; track if you switch.

✗

Unbranded blister or counterfeit risk

Counterfeit pharmaceuticals are a known issue; verify pharmacy and lot if buying internationally.

What to Expect

Day 1
PK-driven acute peak per administration. Verify dose tolerated.
Week 1
Steady-state reached for most daily-dosed pharma.
Week 2-4
Therapeutic effect established; titration window if needed.
Long-term
Periodic monitoring per drug class (labs, BP, ECG as applicable).

Side Effects & Safety 6

Side Effects

1(None reach >10% in most trials at standard doses; telmisartan is one of the cleanest cardiovascular drugs in the formulary.)
2Dizziness / orthostatic hypotension (especially first 1-2 weeks)
3Mild headache (usually self-limited)
4Upper respiratory symptoms (statistically detectable vs placebo, mechanism unclear, usually not bothersome)
5Back pain (occasional)
6Mild fatigue (especially if BP drops too low)

When to Stop

Angioedema — much rarer with ARBs than ACEi but can occur. Lip/tongue/throat swelling → ER. Higher risk in patients with prior ACEi-induced angioedema; telmisartan still possible but reduced.
Hyperkalemia — small risk, more relevant if combined with K+-sparing diuretics, NSAIDs, K+ supplements, or in renal impairment. Usually subclinical at standard doses in healthy users.
Acute kidney injury — rare; risk concentrates in volume-depleted patients, bilateral renal artery stenosis, or NSAID co-use.
Fetal toxicity — ARBs are contraindicated in pregnancy (oligohydramnios, fetal renal failure). Not relevant for users in this archetype but always worth flagging.
Severe hypotension in volume-depleted or salt-restricted patients with first dose.
First 1-2 weeks: orthostasis, mild dizziness; resolves as BP stabilizes.
First 4 weeks: check K+ and creatinine if any pre-existing renal/electrolyte concern; not necessary in healthy users.
Ongoing: annual BMP (K+, creatinine, eGFR) once chronic.